Osteoporosis Prevention and Management — MCQs
What is the gold standard for the diagnosis of osteoporosis?
A 70-year-old female has been on alendronate for 7 years for osteoporosis and now complains of pain in her right thigh. What is the next investigation to be performed?
A 60-year-old elderly female with a previous history of a Colles fracture is now complaining of backache. Which of the following statements regarding the treatment of this patient is incorrect?
Which of the following is not true regarding estrogen use in postmenopausal osteoporosis management?
Prevention or treatment of osteoporosis in post- menopausal women may be achieved by all EXCEPT
Minimum age for routine screening of osteoporosis in women according to USPSTF guidelines:
A female is on hormone replacement therapy for her menopausal symptoms. She is worried about her bone strength because her mom and sister had osteoporosis after the age of 50. All are given for prevention of osteoporosis along with hormonal replacement therapy, EXCEPT:
Hormone Replacement therapy is not indicated in:
HRT in post-menopausal women is given for all except:
Hormone Replacement therapy is not indicated in:
Osteoporosis Prevention and Management Indian Medical PG Practice Questions and MCQs
Question 1: What is the gold standard for the diagnosis of osteoporosis?
- A. Dual energy X-ray absorptiometry (Correct Answer)
- B. Single energy X-ray absorptiometry
- C. Ultrasound
- D. Quantitative computed tomography
Explanation: ***Dual energy X-ray absorptiometry*** - **DXA** is the current **gold standard** for diagnosing osteoporosis and assessing fracture risk due to its high precision and accuracy in measuring **bone mineral density (BMD)**. - It measures BMD at clinically relevant sites such as the **lumbar spine** and **hip**, providing T-scores and Z-scores for comparison. *Single energy X-ray absorptiometry* - **SXA** measures BMD at peripheral sites but is **less accurate** and comprehensive than DXA for diagnosing osteoporosis. - It has **limited utility** as a diagnostic tool for osteoporosis at the hip or spine, which are critical sites for fracture risk. *Ultrasound* - **Quantitative ultrasound (QUS)** can assess bone quality but is primarily used for **screening** and is not accurate enough for definitive diagnosis or treatment monitoring of osteoporosis. - It does **not provide direct bone mineral density measurements** comparable to DXA for diagnostic purposes. *Quantitative computed tomography* - **QCT** can measure volumetric bone density and is useful for assessing **trabecular bone**, but involves higher radiation exposure than DXA. - It is **more expensive** and less readily available than DXA, making it a secondary option for osteoporosis diagnosis.
Question 2: A 70-year-old female has been on alendronate for 7 years for osteoporosis and now complains of pain in her right thigh. What is the next investigation to be performed?
- A. DEXA scan
- B. Serum vitamin D levels
- C. Serum alkaline phosphate levels
- D. X-ray (Correct Answer)
Explanation: **X-ray** - Alendronate, a **bisphosphonate**, is associated with **atypical femoral fractures** after prolonged use, and an X-ray is the most appropriate initial investigation to visualize such a fracture. - Complaints of thigh pain in a patient on long-term bisphosphonate therapy should prompt imaging to rule out this serious complication. *DEXA scan* - A DEXA scan assesses **bone mineral density** but does not provide information about acute fractures or structural integrity in response to specific pain. - While it's used for osteoporosis diagnosis and monitoring, it won't directly identify an atypical femoral fracture. *Serum vitamin D levels* - Maintaining adequate **vitamin D levels** is important for bone health, but its measurement won't explain acute thigh pain or identify a fracture. - Low vitamin D levels can contribute to osteoporosis but are not the primary cause of pain suggestive of an atypical femoral fracture. *Serum alkaline phosphate levels* - **Alkaline phosphatase** levels can be elevated in conditions involving increased bone turnover, such as healing fractures or certain bone diseases. - However, it is not a direct diagnostic tool for identifying atypical femoral fractures and would not be the first line investigation.
Question 3: A 60-year-old elderly female with a previous history of a Colles fracture is now complaining of backache. Which of the following statements regarding the treatment of this patient is incorrect?
- A. Oral vitamin D3 is given along with oral calcium
- B. Teriparatide should be started before supplementing bisphosphonates (Correct Answer)
- C. Calcium requirement is 1200 mg per day
- D. Bisphosphonates can be given for 3-5 years depending on patient response and risk factors
Explanation: ***Teriparatide should be started before supplementing bisphosphonates*** - This statement is incorrect because **bisphosphonates are typically the first-line treatment** for osteoporosis, especially in patients with a history of fragility fractures like a Colles fracture. - **Teriparatide**, an anabolic agent, is usually reserved for patients with very severe osteoporosis, those who have failed bisphosphonate therapy, or those with highly accelerated bone loss. *Oral vitamin D3 is given along with oral calcium* - This is a routine and **correct practice in osteoporosis management** as calcium and vitamin D are essential for bone health. - **Vitamin D** aids in calcium absorption from the gut, and both are crucial for bone mineralization and density. *Calcium requirement is 1200 mg per day* - The recommended daily **calcium intake for postmenopausal women** and elderly individuals with osteoporosis is typically around 1200 mg. - This amount helps to maintain skeletal health and reduce the risk of fractures. *Bisphosphonates can be given for 3-5 years depending on patient response and risk factors* - This statement is correct, as **bisphosphonates are commonly prescribed for 3-5 years** to reduce fracture risk in osteoporosis. - A **"drug holiday"** may be considered after this period, depending on the patient's fracture risk and bone mineral density.
Question 4: Which of the following is not true regarding estrogen use in postmenopausal osteoporosis management?
- A. Improves bone density
- B. Lowers breast cancer risk (Correct Answer)
- C. Increases thromboembolism risk
- D. May cause endometrial hyperplasia
Explanation: ***Lowers breast cancer risk*** - Estrogen use, particularly **combined estrogen-progestin therapy**, actually **increases** the risk of breast cancer, rather than lowering it [1]. - This increased risk is a significant concern and a primary reason why estrogen therapy is not a first-line treatment for osteoporosis [1]. *Improves bone density* - Estrogen therapy is known to **prevent bone loss** and **increase bone mineral density** in postmenopausal women by inhibiting osteoclast activity [1]. - This effect is beneficial in reducing the risk of osteoporotic fractures [1], [2]. *Increases thromboembolism risk* - Estrogen therapy significantly **increases the risk of venous thromboembolism (VTE)**, including deep vein thrombosis and pulmonary embolism. - This is a well-established adverse effect and a contraindication in women with a history of thrombotic events. *May cause endometrial hyperplasia* - Unopposed estrogen therapy can **stimulate endometrial proliferation**, leading to **endometrial hyperplasia** and an increased risk of endometrial cancer. - This is why progestin is typically added to estrogen therapy in women with an intact uterus.
Question 5: Prevention or treatment of osteoporosis in post- menopausal women may be achieved by all EXCEPT
- A. Calcium and vitamin D supplementation
- B. Multivitamins (Correct Answer)
- C. Bisphosphonates
- D. Estrogen and progesterone hormone replacement therapy
Explanation: ***Multivitamins*** - While multivitamins may contain some **calcium** and **vitamin D**, the dosages are generally insufficient to effectively prevent or treat osteoporosis, which requires targeted, higher doses of these specific nutrients. - Multivitamins provide a broad range of vitamins and minerals, many of which are not directly involved in **bone metabolism** or have a significant impact on **bone mineral density**. *Calcium and vitamin D supplementation* - **Calcium** is a fundamental component of bone, and adequate intake is crucial for maintaining **bone mineral density** and strength, especially in postmenopausal women who are at higher risk of osteoporosis [1, 4]. - **Vitamin D** is essential for the absorption of calcium in the gut and plays a key role in regulating **calcium and phosphate homeostasis**, directly impacting bone health [3]. *Bisphosphonates* - **Bisphosphonates** are potent **antiresorptive agents** that inhibit **osteoclast activity**, thereby reducing bone turnover and preventing bone loss, making them a cornerstone of osteoporosis treatment. - They effectively increase **bone mineral density** and significantly reduce the risk of **vertebral and non-vertebral fractures** in postmenopausal women. *Estrogen and progesterone hormone replacement therapy* - **Estrogen deficiency** after menopause is a primary cause of accelerated bone loss; **estrogen replacement therapy** helps to maintain bone density by reducing **bone resorption** [2]. - While effective, HRT is typically reserved for women with significant menopausal symptoms or those who cannot tolerate other osteoporosis treatments, due to potential risks like increased risk of **breast cancer** and **cardiovascular events** [2].
Question 6: Minimum age for routine screening of osteoporosis in women according to USPSTF guidelines:
- A. 55 years
- B. 60 years
- C. 50 years
- D. 65 years (Correct Answer)
Explanation: ***65 years*** - The **U.S. Preventive Services Task Force (USPSTF)** recommends routine osteoporosis screening with **bone mineral density (BMD) testing** for all women aged 65 years and older. - This recommendation is based on evidence that screening in this age group can effectively reduce the risk of **osteoporotic fractures**. *55 years* - This age is **too early** for routine osteoporosis screening in women according to current USPSTF guidelines. - Screening before age 65 is recommended only for younger women at **increased risk** of osteoporosis. *60 years* - This age is also **too early** for routine osteoporosis screening in women without additional risk factors. - The benefits of universal screening typically outweigh the harms beginning at age 65. *50 years* - This age is generally considered **too young** for routine osteoporosis screening. - Women in this age group are often still premenopausal or early postmenopausal and typically do not have a sufficiently high risk to warrant routine screening.
Question 7: A female is on hormone replacement therapy for her menopausal symptoms. She is worried about her bone strength because her mom and sister had osteoporosis after the age of 50. All are given for prevention of osteoporosis along with hormonal replacement therapy, EXCEPT:
- A. Calcium
- B. Vitamin-E (Correct Answer)
- C. Vit.D
- D. None of the options
Explanation: ***Vitamin-E*** - **Vitamin-E** is an **antioxidant** vitamin that primarily protects cells from oxidative damage. - It does not play a direct role in **bone metabolism** or the prevention of osteoporosis. *Calcium* - **Calcium** is a fundamental component of bone tissue and is essential for maintaining **bone density** [1]. - Adequate calcium intake is crucial for **osteoporosis prevention**, especially in postmenopausal women [1], [2]. *Vit.D* - **Vitamin D** is essential for **calcium absorption** in the gut and its incorporation into bones. - Without sufficient Vitamin D, calcium cannot be effectively utilized, leading to compromised **bone health**. *None of the options* - This option is incorrect because Vitamin E does not contribute to osteoporosis prevention, making it the correct answer to the "EXCEPT" question. - Calcium and Vitamin D are both vital for bone strength, so stating that none of the options fit would be inaccurate [1].
Question 8: Hormone Replacement therapy is not indicated in:
- A. Vaginal atrophy
- B. Osteoporosis
- C. Prevention of CAD (Correct Answer)
- D. Hot flashes
Explanation: ***Prevention of CAD*** - Hormone replacement therapy (HRT) is **not indicated** for the primary or secondary prevention of **Coronary Artery Disease (CAD)**. While observational studies initially suggested a benefit, large randomized controlled trials (e.g., WHI) showed no cardiovascular protection and even an increased risk of stroke and venous thromboembolism. - The benefits of HRT for menopausal symptoms generally outweigh the risks only in select women, and CAD prevention is not one of them. *Vaginal atrophy* - **Vaginal atrophy**, characterized by dryness, irritation, and painful intercourse, is a common menopausal symptom effectively treated with **local estrogen therapy**. - Systemic HRT can also alleviate these symptoms, but local therapy is often preferred for isolated vaginal symptoms to minimize systemic exposure. *Osteoporosis* - HRT, particularly estrogen therapy, is an effective treatment for the **prevention and management of postmenopausal osteoporosis**, preventing bone loss and reducing the risk of fractures. - However, it is generally considered a second-line option for osteoporosis, after non-hormonal therapies, due to potential risks. *Hot flashes* - **Hot flashes** (vasomotor symptoms) are one of the most common and bothersome symptoms of menopause, and **systemic HRT** is the **most effective treatment** available. - Estrogen therapy significantly reduces the frequency and severity of hot flashes, improving quality of life for many women.
Question 9: HRT in post-menopausal women is given for all except:
- A. Hot flushes
- B. Prevention of coronary artery disease (Correct Answer)
- C. Vaginal dryness
- D. Prevention of osteoporosis
Explanation: ***Prevention of coronary artery disease*** - While previously thought to be protective, later studies like the **Women's Health Initiative (WHI)** demonstrated that HRT can actually **increase the risk of cardiovascular events**, especially when initiated years after menopause. - HRT is **not recommended for the primary or secondary prevention** of coronary artery disease. *Hot flushes* - **Hot flushes** (vasomotor symptoms) are a common and effective indication for HRT, significantly reducing their frequency and severity. - Estrogen therapy is considered the **most effective treatment** for moderate to severe hot flashes associated with menopause. *Vaginal dryness* - **Vaginal dryness** (vulvovaginal atrophy) is effectively treated by HRT, particularly with local estrogen therapy, by restoring vaginal tissue health. - Estrogen helps to **restore the thickness, elasticity, and lubrication** of the vaginal walls, alleviating discomfort. *Prevention of osteoporosis* - HRT, specifically estrogen, is effective in **preventing bone loss** and reducing the risk of **osteoporotic fractures** in postmenopausal women. - It maintains **bone mineral density** by inhibiting osteoclast activity and promoting osteoblast function.
Question 10: Hormone Replacement therapy is not indicated in:
- A. Hot flashes
- B. Prevention of CAD (Correct Answer)
- C. Osteoporosis
- D. Vaginal atrophy
Explanation: ***Prevention of CAD*** - Hormone replacement therapy (HRT) is **not indicated for the primary or secondary prevention of coronary artery disease** (CAD) due to potential cardiovascular risks. - Studies, such as the Women's Health Initiative (WHI), have shown that HRT may **increase the risk of cardiovascular events**, especially in older women or those initiating therapy years after menopause. *Hot flashes* - HRT is considered the **most effective treatment for severe vasomotor symptoms**, such as hot flashes and night sweats, associated with menopause. - Estrogen therapy significantly reduces the frequency and severity of these symptoms, improving the **quality of life** for menopausal women. *Osteoporosis* - Estrogen is crucial for maintaining bone density, and HRT is a proven method for **preventing and treating postmenopausal osteoporosis**. - It helps reduce bone resorption and decrease the risk of **osteoporotic fractures**. *Vaginal atrophy* - HRT, particularly **local estrogen therapy**, is highly effective in relieving symptoms of vulvovaginal atrophy, such as vaginal dryness, itching, and dyspareunia. - It restores the **vaginal epithelium** and improves vaginal health by increasing blood flow and lubrication.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free